Inaktiver Wert

Andere Sprachen Incannex Healthcare Australian S.E.

Aktien

A2DF4D

AU000000IHL8

IHL

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	30.05.
Incannex Healthcare Inc. Announces Patient Dosing Commencement in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	30.05.
Incannex Healthcare Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	15.05.
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder	07.05.
Incannex Complete Successful Pre-Ind Meeting with the Fda for Cannquit-O for Treatment of Opioid Use Disorder	07.05.
Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)	01.05.
Incannex Healthcare Inc. Quarterly Update, Q1 2024	16.04.
Incannex Healthcare Inc. Announces CFO Changes	05.03.
Incannex Healthcare Inc. Announces Executive Changes	05.03.
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder	28.02.
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder	28.02.
Incannex Healthcare Completes Pre-Investigational New Drug Meeting on CannQuit-N With US FDA	16.02.
Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation	16.02.
Incannex Healthcare Inc. Completes Successful Pre-IND Meeting with the FDA for CannQuit-N	16.02.
Incannex Healthcare Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	14.02.
Clarion Clinics Open for Psychedelic-Assisted Treatments	01.02.
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis	24.01.
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis	24.01.
Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences	18.01.
Incannex Completes Dosing and Therapy in Phase 2 ?Psigad? Clinical Trial Assessing Psilocybin-Assisted Psychotherapy for Generalized Anxiety Disorder	18.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Incannex Healthcare Australian S.E.

Aktien

A2DF4D

AU000000IHL8

IHL

Andere Sprachen

Filter